Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL Inactivated Influenza Vaccine in Adults
NCT00333398Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2006
- Primary completion
- Aug 2006
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Influenza A (H1N1) vaccine in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Seroprotection Rate at Day 21 and Seroconversion Rate at Day 21. Started Jun 2006; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00333398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333398.